Oral presentation at ECCO’22, February 16-19, 2022.

Oral presentation at ECCO'22, February 16-19, 2022.

An artificial intelligence–driven scoring system to measure histological disease activity in ulcerative colitis

An abstract ‘An artificial intelligence–driven scoring system to measure histological disease activity in ulcerative colitis‘, will be presented as an oral presenation at the European Crohn’s and Colitis Organization (ECCO) meeting, 16-18 February 2022.

The authors Laurent Peyrin-Biroulet, Shashi Adsul, Jamshid Dehmeshki, and Olga Kubassova from the Nancy University Hospital and INSERM U1256 Nutrition-Genetics and Environmental Risk Exposure, Lorraine University, Vandoeuvre-lès-Nancy, France; Takeda, Zurich, Switzerland;  and IAG, Image Analysis Group, London, UK, will be attending the meeting in the virtual format.

The objective of the publication is to present the novel artificial intelligence (AI) powered tool that will potentially allow gastroenterologists to effectively incorporate histology (the study of the microscopic structure of tissues) in their real-life assessment of people suffering from UC.

The parties utilized an AI-driven approach to augment clinical decision making when assessing disease activity and the efficacy of treatments in UC.

Prof. Laurent Peyrin-Biroulet, Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, the scientific lead on this project, said “The success of patient treatment with novel therapeutic agents highly depends on the efficient use of modern technologies and data-centric development approaches. In such a critical area as IBD, our patients will no doubt will benefit from the use of Artificial Intelligence to augment clinical decisions.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

About Takeda Pharmaceutical Company Limited